enGene Therapeutics Inc. (FRA:S0N0)
Germany · Delayed Price · Currency is EUR | Market Cap | 107.34M -42.9% |
| Revenue (ttm) | n/a |
| Net Income | -108.13M |
| EPS | -1.81 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.504 |
| Previous Close | 1.454 |
| Day's Range | 1.504 - 1.504 |
| 52-Week Range | 1.016 - 10.100 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 9, 2026 |
About enGene Therapeutics
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based... [Read more]
News
enGene Therapeutics Transcript: KOL event
The NMIBC market is expanding with increased sequencing and new therapies, especially for high-risk BCG-unresponsive patients. Detalimogene's non-viral profile, efficacy, and ease of use position it for strong adoption in community practices, with favorable pricing and reimbursement dynamics supporting its commercial potential.
enGene Therapeutics Slides: KOL event
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtu...
enGene announces changes to board, appoints Heffernan as Chairman
enGene (ENGN) Therapeutics announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid if approved. Det...
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of D...
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to ...
enGene Therapeutics Slides: Corporate presentation
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
enGene downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley downgraded enGene (ENGN) to Underweight from Equal Weight without a price target The firm’s checks show reduced confidence from physicians that enGene’s LEGEND study will support signif...
enGene price target lowered to $4 from $6 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on enGene (ENGN) to $4 from $6 and keeps a Buy rating on the shares following the Q2 report. The firm is waiting…
enGene implements plan to reduce workforce by 50%
In June, enGene (ENGN) implemented a plan to reduce its workforce by approximately 50% to streamline operations and preserve cash. The Company has retained personnel and resources required to meet…
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial results for ...
enGene Therapeutics Earnings release: Q2 2026
enGene Therapeutics released its Q2 2026 earnings on June 15, 2026, summarizing the period's financial results.
enGene Therapeutics Quarterly report: Q2 2026
enGene Therapeutics has published its Q2 2026 quarterly earnings report on June 15, 2026.
enGene Therapeutics Transcript: AGM 2026
The meeting confirmed quorum, reviewed and approved the election of four directors until 2029, and reappointed KPMG LLP as auditor. All proposals passed with strong shareholder support, and no questions were raised on the main items.
enGene price target lowered to $2 from $9 at UBS
UBS lowered the firm’s price target on enGene (ENGN) to $2 from $9 and keeps a Neutral rating on the shares.
Leerink downgraded enGene to Market Perform following LEGEND update
As previously reported, Leerink downgraded enGene (ENGN) to Market Perform from Outperform with a price target of $2, down from $19, following the “disappointing” LEGEND update as key debates around…
enGene downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded enGene (ENGN) to Perform from Outperform. The firm views updated interim data from the pivotal LEGEND cohort in BCG-unresponsive NMIBC as disappointing, and while the approval d...
enGene downgraded to Market Perform from Outperform at Leerink
Leerink downgraded enGene (ENGN) to Market Perform from Outperform with a $2 price target
enGene Therapeutics Proxy statement: Proxy filing
enGene Therapeutics filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
enGene downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgraded enGene (ENGN) to Outperform from Strong Buy with a price target of $4, down from $27, after the company announced interim results from the pivotal cohort of…
enGene downgraded to Neutral from Buy at Guggenheim
Guggenheim yesterday downgraded enGene (ENGN) to Neutral from Buy without a price target after the company announced interim results from the pivotal cohort of LEGEND, evaluating detalimogene in BCG-u...
enGene downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Allison Bratzel downgraded enGene (ENGN) to Neutral from Overweight with a price target of $4, down from $7, after the company announced interim results from the pivotal…
enGene downgraded to Market Perform from Outperform at Citizens
Citizens downgraded enGene (ENGN) to Market Perform from Outperform without a price target The company’s updated results from the pivotal LEGEND study “worsened significantly,” the analyst tells inves...
enGene downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded enGene (ENGN) to Equal Weight from Overweight with a price target of $2, down from $25. The company’s efficacy data for detalimogene is weaker than the last…
enGene downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Judah Frommer downgraded enGene (ENGN) to Equal Weight from Overweight without a price target after the company announced interim results from the pivotal cohort of LEGEND, eval...